奥氮平与齐拉西酮治疗精神分裂症的疗效及对糖脂代谢的影响

目的 探讨奥氮平与齐拉西酮治疗精神分裂症的疗效及对糖脂代谢的影响。 方法 收集绍兴市第七人民医院2014年3月—2017年1月收治的90例精神分裂症患者,按照随机数字表法分为A组和B组,每组45例,其中A组患者给予齐拉西酮治疗、B组给予奥氮平治疗,比较2组患者的临床治疗效果以及糖脂代谢指标。 结果 治疗前和治疗后2、4、6周2组PANSS和CGI-S评分组间差异无统计学意义(均P>0.05);A组和B组治疗4、6周阳性症状分、阴性症状分、一般精神分及PANSS总评分均低于治疗前相应评分(均P<0.05);A组和B组治疗2、4、6周CGI-S评分低于治疗前相应评分(均P<0.05);A组治疗有效率为97.78%,高于B组的82.22%(P<0.05);治疗6周后B组FBS、INS、LDL水平均高于A组治疗6周后,差异具有统计学意义(均P<0.05),A组治疗6周后FBS降低,INS、LDL、HDL、CHOL及TG升高,B组治疗6周后FBS、INS、LDL、HDL、CHOL及TG均升高,差异具有统计学意义(均P<0.05)。 结论 齐拉西酮和奥氮平治疗精神分裂症的临床效果无明显差别,但齐拉西酮对患者糖脂代谢影响相对较小。 

Efficacy of olanzapine and ziprasidone in the treatment of schizophrenia and their effect on glucose and lipid metabolism

Objective To investigate the efficacy of olanzapine and ziprasidone in the treatment of schizophrenia and their effects on glucose and lipid metabolism. Methods Ninety patients with schizophrenia admitted in our hospital from March 2014 to January 2017 were divided into group A and group B according to the random number table method, 45 patients in each group. Group A was treated with ziprasidone, and Group B was treated with olanzapine. The efficacy, glucose and lipid metabolism were compared between the two groups at 6 weeks after treatment. Results There was no difference in PANSS and CGI-S scores between the two groups before and 2, 4, and 6 weeks after treatment(all P>0.05). The scores of positive symptoms, negative symptoms, general spirit and PANSS of group A and group B treated for 4 and 6 weeks were lower than those before treatment(all P<0.05). The effective rate of treatment in group A was 97.78%, higher than 82.22% in group B(P<0.05). After 6 weeks of treatment, the FBS decreased, and INS, LDL, HDL, CHOL, TG increased in group A; the FBS, INS, LDL, CHOL and TG increased in group B; the FBS, INS, and LDL levels in group B were higher than those in group A; the differences were statistically significant(all P<0.05). Conclusion There was no significant difference between ziprasidone and olanzapine in treatment of schizophrenia, but the effect of ziprasidone on glucose and lipid metabolism is relatively small.